Iradimed Corp. (IRMD) Tops Q4 EPS by 4c, Slight Beat on Revenues; Offers FY18 EPS/Revenue Guidance Above Consensus

Iradimed Corp. (NASDAQ: IRMD) reported Q4 EPS of $0.10, $0.04 better than the analyst estimate of $0.06. Revenue for the quarter came in at $6.7 million versus the consensus estimate of $6.61 million.

• Reports fourth quarter 2017 revenue of $6.7 million
• Reports fourth quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.10
• Records one-time non-cash charge of $0.5 million related to tax reform

Financial Guidance

On January 22, 2018, the Company provided revenue, GAAP and non-GAAP diluted earnings guidance for the full year and first quarter 2018.

For the full year 2018, the Company expects to report revenue of $29.3 million to $30.0 million, GAAP diluted earnings per share of $0.22 to $0.27 and non-GAAP diluted earnings per share of $0.33 to $0.38.

For the first quarter 2018, the Company expects to report revenue of $6.8 million to $6.9 million, GAAP diluted earnings per share of $0.04 to $0.05 and non-GAAP diluted earnings per share of $0.06 to $0.07.

The Company’s non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be approximately $1.3 million and $0.3 million for the full year and first quarter 2018, respectively.

GUIDANCE:

Iradimed Corp. sees FY2018 EPS of $0.33-$0.38, versus the consensus of $0.33. Iradimed Corp. sees FY2018 revenue of $29.3-30 million, versus the consensus of $28.8 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• BofA lists top 5 themes driving next $1tn in incremental semi sales